OncoPharm Bleomycin
25 snips
Mar 27, 2020 Explore the fascinating origins and pharmacology of bleomycin, a unique chemotherapy drug. Discover its mechanism of action, including minimal myelosuppression and distinct pulmonary toxicity risks. The discussion also highlights its effective use in treating Hodgkin's and testicular cancer. Transitioning to personal reflections on COVID-19, the host shares emotional impacts, resource management in oncology, and strategies for coping during challenging times. Tune in for insights into both oncology and the pandemic experience!
AI Snips
Chapters
Transcript
Episode notes
Mechanism, Size, And Clearance
- Bleomycin binds DNA and in the presence of oxygen and iron produces free radicals that cause single and double strand breaks leading to G2 arrest.
- Its large size prevents CNS penetration and it is primarily renally eliminated with degradation by bleomycin hydrolase.
Primary Clinical Uses Today
- Bleomycin is used with curative intent mainly in Hodgkin's lymphoma and testicular (germ cell) cancers as part of multi-agent regimens.
- It also serves as a pleural sclerosing agent for malignant effusions.
Monitor DLCO Regularly
- Obtain baseline pulmonary function tests and monitor DLCO before and during bleomycin therapy to detect early toxicity.
- Stop bleomycin if DLCO falls by roughly 20–35% from baseline to avoid progression to fibrosis.